John Mumm

Company: Deka

Job title: President &Chief Executive Officer

Seminars:

Panel Discussion 2:30 pm

Discussing the key challenges and opportunities in animal models for cytokine drug development to overcome the translation phase and succeed in the clinic Attendees will have the opportunity to ask questions and engage in discussion with the panelistsRead more

day: Conference Day Two

Controlling the Achillies Heel of all T Cell Directed Therapies; Suppression of IL-2 Mediated Cytokine Release Syndrome by Combination with IL-10 12:45 pm

Discussing the therapies designed to enhance anti-tumor T cell efficacy and how they all share a common liability, the unpredictable induction of cytokine release syndrome (CRS) that is dissociated from efficacy Investigating how, independent of the mode of stimulation, activation of T cells results in secretion of IL-2 Exploring IL-2 receptor binding leads to the…Read more

day: Conference Day One